Trial · NCT01907100
Adverse events976
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 976
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Placebo_Phase II | 9 | 41 | |
| other | Anaemia | Blood and lymphatic system disorders | Nintedanib_Phase II | 16 | 44 | |
| other | Anaemia | Blood and lymphatic system disorders | Placebo_Phase III | 94 | 228 | |
| other | Anaemia | Blood and lymphatic system disorders | Nintedanib_Phase III | 76 | 227 | |
| other | Leukopenia | Blood and lymphatic system disorders | Placebo_Phase II | 5 | 41 | |
| other | Leukopenia | Blood and lymphatic system disorders | Nintedanib_Phase II | 2 | 44 | |
| other | Leukopenia | Blood and lymphatic system disorders | Placebo_Phase III | 28 | 228 | |
| other | Leukopenia | Blood and lymphatic system disorders | Nintedanib_Phase III | 20 | 227 | |
| other | Neutropenia | Blood and lymphatic system disorders | Placebo_Phase II | 9 | 41 | |
| other | Neutropenia | Blood and lymphatic system disorders | Nintedanib_Phase II | 22 | 44 | |
| other | Neutropenia | Blood and lymphatic system disorders | Placebo_Phase III | 82 | 228 | |
| other | Neutropenia | Blood and lymphatic system disorders | Nintedanib_Phase III | 83 | 227 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Placebo_Phase II | 1 | 41 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Nintedanib_Phase II | 7 | 44 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Placebo_Phase III | 18 | 228 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Nintedanib_Phase III | 13 | 227 | |
| other | Tinnitus | Ear and labyrinth disorders | Placebo_Phase II | 9 | 41 | |
| other | Tinnitus | Ear and labyrinth disorders | Nintedanib_Phase II | 4 | 44 | |
| other | Tinnitus | Ear and labyrinth disorders | Placebo_Phase III | 24 | 228 | |
| other | Tinnitus | Ear and labyrinth disorders | Nintedanib_Phase III | 15 | 227 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01907100/events